These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 36794894)

  • 1. Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
    Boesjes CM; Van der Gang LF; Zuithoff NPA; Bakker DS; Spekhorst LS; Haeck I; Kamsteeg M; De Graaf M; De Bruin-Weller MS
    Acta Derm Venereol; 2023 Feb; 103():adv00872. PubMed ID: 36794894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
    Boesjes CM; Kamphuis E; Zuithoff NPA; Bakker DS; Loman L; Spekhorst LS; Haeck I; Kamsteeg M; Van Lynden-van Nes AMT; Garritsen FM; Politiek K; Oldhoff M; De Graaf M; Schuttelaar MLA; De Bruin-Weller MS
    Acta Derm Venereol; 2022 Nov; 102():adv00820. PubMed ID: 36420885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
    Kamphuis E; Boesjes CM; Loman L; Kamsteeg M; Haeck I; Van Lynden-van Nes AMT; Politiek K; Van der Gang LF; De Graaf M; De Bruin-Weller MS; Schuttelaar MLA
    Acta Derm Venereol; 2024 Feb; 104():adv19454. PubMed ID: 38323500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
    Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients.
    Napolitano M; Ferrucci SM; Foggia L; Hansel K; Pezzolo E; Stingeni L; Antonelli E; Picone V; Patruno C
    Clin Drug Investig; 2024 Jan; 44(1):71-77. PubMed ID: 38105393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan.
    Hagino T; Yoshida M; Hamada R; Saeki H; Fujimoto E; Kanda N
    J Dermatolog Treat; 2023 Dec; 34(1):2276043. PubMed ID: 38073228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan.
    Hagino T; Hamada R; Yoshida M; Saeki H; Fujimoto E; Kanda N
    Clin Drug Investig; 2024 Apr; 44(4):261-269. PubMed ID: 38446396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
    Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
    Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study.
    Huang D; Lu J; Tan F
    Dermatitis; 2024; 35(1):77-83. PubMed ID: 37930745
    [No Abstract]   [Full Text] [Related]  

  • 12. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry.
    Kamphuis E; Loman L; Han HL; Romeijn GLE; Politiek K; Schuttelaar MLA
    Contact Dermatitis; 2023 May; 88(5):351-362. PubMed ID: 36621910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
    Drucker AM; Morra DE; Prieto-Merino D; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
    JAMA Dermatol; 2022 May; 158(5):523-532. PubMed ID: 35293977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
    Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K;
    Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.
    De Greef A; Ghislain PD; de Montjoye L; Baeck M
    Adv Ther; 2023 May; 40(5):2509-2514. PubMed ID: 36944819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
    Wan H; Jia H; Xia T; Zhang D
    Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatolog Treat; 2024 Dec; 35(1):2344591. PubMed ID: 38653561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective.
    Johansson E; Giovannitti M; Mezzetti M; Lu N; Sabatino S
    J Med Econ; 2023; 26(1):1155-1166. PubMed ID: 37674383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Efficacy of Baricitinib and Dupilumab in the Treatment of Chinese Moderate-To-Severe Atopic Dermatitis: A Retrospective Study.
    Liu B; Song X; Liao S; Luan T; Zhao Z
    Int Arch Allergy Immunol; 2023; 184(10):966-974. PubMed ID: 37245505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
    Kamphuis E; Boesjes CM; Loman L; Bakker DS; Poelhekken M; Zuithoff NPA; Kamsteeg M; Romeijn GLE; van Wijk F; de Bruin-Weller MS; de Graaf M; Schuttelaar MLA
    Pediatr Allergy Immunol; 2022 Dec; 33(12):e13887. PubMed ID: 36564878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.